奥罗芬治疗侵袭性真菌病中的矛盾性加重现象
该研究基于IIb期试验及后续管理准入计划(合计N=470),描述了接受奥罗芬治疗的侵袭性真菌病患者中出现的矛盾性反应。共识别6例符合定义的患者,其中4/6免疫功能正常,反应时间从数天到数月不等,所有患者维持奥罗芬治疗且矛盾反应未经特定干预自行缓解,最终均获得治疗成功。
要点
- 奥罗芬治疗中可出现矛盾性加重,需与疾病进展或复发鉴别。
- 矛盾反应时间不定,从数天到数月,多数患者免疫功能正常。
- 维持奥罗芬治疗,矛盾反应可自行缓解,后续治疗成功。
核心结论
- 系统性真菌病治疗中矛盾反应少见,但奥罗芬治疗中可发生,且不改变最终治疗成功。
研究设计与样本
- 基于开放标签单臂IIb期试验(NCT03583164)及后续管理准入计划,合计N=470,纳入透明霉、温双相真菌等患者。
主要发现
- 共识别6例符合矛盾反应定义的患者,其中4/6免疫功能正常。
- 矛盾反应发生时间从数天到数月不等,所有患者维持奥罗芬治疗,反应自行缓解,最终均治疗成功。
关键数值与推荐
- 矛盾反应定义为启动奥罗芬治疗后出现临床或影像学加重,且无证据表明基础疾病恶化/复发或存在替代诊断。
临床怎么用
- 临床医生使用奥罗芬时应知晓矛盾反应可能,避免误判为治疗失败而更改方案。
局限性
- 病例数少(6例),来自试验和管理准入计划,代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Paradoxical reactions to appropriate antimicrobial therapy are seldom reported in systemic fungal diseases. Olorofim (formerly F901318) is an orally available first-in-class antifungal and exhibits in vitro killing. Recently, an open-label, single-arm phase IIb study (NCT03583164) enrolling patients with invasive fungal diseases for which there were limited or no other treatment options was completed. During the conduct of this trial, several investigators noted a transient worsening of disease in a subset of treated patients despite subsequent improvement, and we aimed to describe these patients in detail to assist clinicians prescribing olorofim treatment. METHODS: Detailed methods and results of the phase 2b trial have been previously described, and a subsequent managed access programme used the same rules as the phase 2b study for enrolment (combined N = 470). Briefly, patients with hyaline moulds, thermally dimorphic fungi, or other fungi requiring sponsor approval were enrolled and given olorofim therapy. A paradoxical reaction was defined as worsening clinical or radiological findings following initiation of treatment (olorofim) in the absence of evidence for underlying disease worsening/relapse or the presence of an alternative diagnosis after initiation of treatment. RESULTS: Case review identified six patients meeting criteria, and 4/6 were immunocompetent. The timing of paradoxical responses was variable and ranged from days to months following initiation of olorofim. All patients were maintained on olorofim and paradoxical reactions resolved without specific intervention, and all patients exhibited a subsequent successful response to therapy. CONCLUSIONS: Paradoxical reactions to appropriate antimicrobial therapy are infrequently observed in systemic fungal diseases. Similar responses are seen in the treatment of both tuberculosis (worsening of lymphadenitis) and leprosy (reversal reactions), suggesting a similar pathophysiologic mechanism may be responsible given the overlapping immune response between mycobacterial and fungal pathogens. Awareness of this potential syndrome is essential during the treatment of patients with olorofim therapy.
引用
- Thompson GR, Bruns AHW, Helweg-Larsen J, et al. Paradoxical worsening on olorofim in patients undergoing treatment for invasive fungal diseases. Clin Microbiol Infect. 2025. PMID: 41475489. doi:10.1016/j.cmi.2025.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。